Core Viewpoint - The company is transforming its international business model from traditional product export to an integrated platform approach, focusing on building a global health ecosystem through collaboration with local healthcare systems and public health institutions [2] Group 1: International Market Strategy - The company aims to upgrade its international business from "single-point cooperation" to "ecological collaboration" by leveraging a "platform integration and diagnostic integration" strategy [2] - In response to the high standards and specialization demands of the European market, the company is developing a tailored ecosystem model that includes "high-end diagnostics, customized services, and partner collaboration" [2] Group 2: Sales and Localization - The company's sales strategy primarily relies on distribution, supplemented by direct sales, utilizing local subsidiaries in countries like France and the UK to enhance market penetration [2] - The company is focused on building localized teams, regional service networks, and implementing benchmark projects to strengthen its international ecological construction [2]

Core Viewpoint - The company is focusing on building a global health ecosystem through "platform integration and diagnostic integration," enhancing international business from "single-point cooperation" to "ecological collaboration" [2] Group 1: International Strategy - The company aims for significant development in overseas markets by 2025, steadily expanding its business footprint and improving global resource allocation efficiency [2] - The acquisition of Germany's inno-train Diagnostik GmbH in January is a key strategic move to strengthen the company's global presence in high-end blood molecular diagnostics [2] Group 2: Financial Practices - The company places high importance on asset impairment and goodwill assessment, ensuring that annual financial data strictly adheres to accounting standards and is audited [2]